

Table of Contents

Acknowledgment.....	1
Summary	3
RESUME.....	5
Table of Contents	7
PART I: GENERAL INTRODUCTION.....	17
Chapter I: Generalities on asthma	18
I.1 Definition and clinical features of asthma.....	18
I.2 Diagnosis of asthma	18
I.3 Risk factors in asthma	20
<i>I.3.1 Genetic factors and asthma</i>	20
<i>I.3.2 Environmental factors and asthma</i>	22
I.4 Epidemiology and prevalence	22
I.5 The physiopathology of asthma	24
<i>I.5.1 Asthma subtypes</i>	24
<i>I.5.2 Molecular mechanisms and characteristics of asthma</i>	25
A) Airways hyper-responsiveness	25
B) Airways inflammation in asthma.....	26
<i>B.1 Acute inflammation</i>	26
<i>B.2 Chronic inflammation</i>	28
C) Airways remodeling	30
I.6 Asthma therapy	30
<i>I.6.1 Corticosteroids-based treatment and their mechanisms of action</i>	31
<i>I.6.2 Biologicals-based treatment</i>	32
Chapter II: Inflammatory mediators in airways	35
II.1 Pattern Recognition Receptors (PRRs).....	35
<i>II.1.1 Inflammasomes</i>	36
II.1.1.1 NLRP3 inflammasomes	37
A) <i>Activation mechanisms of the NLRP3 Inflammasome Pathway</i>	38
<i>A.1 The canonical NLRP3 inflammasome pathway</i>	38
<i>A.2 The Non-Canonical Inflammasome Pathway</i>	46
<i>A.3 The Alternative inflammasome pathway</i>	47
B) <i>NLRP3 inflammasome-associated cell deaths</i>	47
<i>B.1 Pyroptosis cell death</i>	48
<i>B.2 Inflammasome-mediated apoptosis</i>	51
C) <i>Regulation of the NLRP3 Inflammasome</i>	52

C.1 Regulation by Post-Translational Modifications of NLRP3	52
D) Pharmacological inhibition of NLRP3 Inflammasome activation	53
E) Natural products and NLRP3 inflammasome inhibition	55
II.2 The role of NLRP3 inflammasome in Th2 and Th17 response	56
II.3 Cytokines	57
II.2.1 IL-1 β cytokine.....	58
II.2.2 Interleukin 6.....	59
II.4 NF- κ B Signaling pathway	60
II.5 Purinergic signaling.....	62
Roles of purinergic receptors and purines in the respiratory tract.....	63
II.6 Asthma and commorbidities	63
Chapter III: Generalities on Malaria.....	65
III.1 Definition and prevalence.....	65
III.2 Life cycle of <i>Plasmodium falciparum</i> and associated symptoms.....	65
III.3 Therapeutic targets	67
III.4 Antimalarial resistance	68
III.5 Malaria and inflammation	68
III. 6 Ethnopharmacology and drug discovery	70
Chapter IV Problem statement and objectives of the study.....	70
IV.1 Problem statement.....	70
IV.2 Research objectives.....	71
Specific objectives	72
IV.2 The research strategy.....	72
PART II: RESULTS.....	77
Chapter IV (Article 1): An ethnobotanical survey and inhibitory effects on NLRP3 inflammasomes/ Caspase-1 of herbal recipes' extracts traditionally used in Rwanda for asthma treatment	78
Supplementary material.....	93
Chapter V (Article 2): The Inhibition of NLRP3 Inflammasome and IL-6 Production by <i>Hibiscus noldeae Baker f.</i> Derived Constituents Provides a Link to Its AntiInflammatory Therapeutic Potentials	111
Supplementary material.....	128
Chapter VI (Article 3): <i>In vitro</i> antiplasmodial and cytotoxic activities of compounds from the roots of <i>Eriosema montanum Baker f.</i> (Fabaceae).....	134
Supplementary material.....	142
Chapter VII (Additional results): <i>In vitro</i> evidence of the anti-inflammatory activities of <i>Eriosema montanum</i> and isolated isoflavonoids marked by the inhibition of the NLRP3 inflammasome activation	162
<i>In vitro</i> evidence of the anti-inflammatory activities of <i>Eriosema montanum</i> and its isolated isoflavonoids marked by the inhibition of the NLRP3 inflammasome activation	163

GENERAL DISCUSSION.....	171
CONCLUSIONS AND RECOMMENDATIONS.....	177
GENERAL CONCLUSION AND RECOMMENDATIONS	180
Appendices	195